Effect of Diosmin/Hesperidin Combination on Platinum Compounds-Induced Nephropathy in Cancer Patients

Evaluation of the Effect of Diosmin/Hesperidin Combination on Platinum Compounds-Induced Nephropathy in Cancer Patients: A Randomized Controlled Trial

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT07598214

Acronym

Dios/Hes-PT

Enrollment

100

Registered

2026-05-20

Start date

2025-02-03

Completion date

2026-12-03

Last updated

2026-05-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer Patients

Brief summary

The current study aims to investigate the protective properties of diosmin/hesperidin on cisplatin-induced nephrotoxicity.

Detailed description

The current study is a prospective randomized controlled clinical study that will be conducted on about 100 cancer patients. Study duration The study will be conducted from January 2025 to September 2025 Study population Group I (control): includes 37 cancer patients administrating platinum compounds in their chemotherapeutic cycles as standard therapy. Group II (Test group) includes 37 cancer patients administrating platinum compounds in their chemotherapeutic cycles as standard therapy plus 450 mg diosmin and 50 mg hesperidin combination orally twice daily.

Interventions

COMBINATION_PRODUCTdiosmin/hesperdin

combination of Diosmin and Hesperidin

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

* Patients of 18 to 75 year-age must have histologically or cytologically confirmed cancer by the Laboratory of Pathology receiving a platinum compound chemotherapy.

Exclusion criteria

* -History of allergic reactions attributed to drugs in the study. * Pregnant women. * Life expectancy less than 6 months * Inability or unwillingness to comply with research protocols. * Cancer patients with impaired renal function (creatinine clearance \< 50 mL/min) * Preexisting hearing loss. * Patients taking nephrotoxic drugs; and those who have a history of allergic reactions to platinum-containing compounds.

Design outcomes

Primary

Measure	Time frame	Description
serum creatinine level	6 months following treatment	Serum creatinine will be measured in mg/dl every 2 weeks during the study period.
blood urea level	6 months following treatment	blood urea levels will be measured in mg/dl every 2 weeks during the study period.

Secondary

Measure	Time frame	Description
hemoglobin level	6 months following treatment	Hemoglobin levels will be measured in g/dl every 2 weeks during the study period.

Countries

Egypt

Contacts

CONTACTmarwa mohsen, PhD

marwa.mohsen@pharm.bsu.edu.eg01202203223

PRINCIPAL_INVESTIGATORmarwa mohsen

clinical pharmacy department, Beni Suef University

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 21, 2026